Barclays raised the firm’s price target on Boston Scientific to $70 from $60 and keeps an Overweight rating on the shares after its Q4 results and guidance. Investors expected 2024 growth outlook to be toward the lower end of the company’s long-term growth plan of 8%-10%, and that is exactly what the company delivered, the analyst tells investors in a research note. Farapulse approval coming a month or two early was a positive from the quarter, though this was partially offset by the modest push out of Boston Scientific’s U.S. TAVR launch, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Announces Key Executive Appointments
- Boston Scientific (NYSE:BSX) Surges on Stellar Q4 Results
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific sees FY24 adjusted EPS $2.23-$2.27, consensus $2.24
- Boston Scientific sees Q1 EPS 50c-52c, consensus 52c